Hepatitis GBV-C infection in intravenous drug users.
Our group has investigated 204 intravenous drug users for the presence of GBV-C-RNA by means of reverse transcriptase polymerase chain reaction (RT-PCR). The majority of the individuals tested were male, their age ranging from 16 to 63 years, and the duration of intravenous drug use from one to 40 years. We detected GBV-C-RNA in 46 of the 204 IVDUs (22.5%) with its prevalence peaking in the age group between 21 to 30 years while decreasing with advancing age. Similarly, its frequency was found in inverted relation to the duration of drug use. The present findings strongly hint at the host's immune system's capacity to clear hepatitis GBV-C as opposed to the other blood-borne hepatitis viruses. From the liver function tests performed we could not detect any statistically significant difference regarding ALT elevation observed in GBV-C-positive as compared to GBV-C-negative individuals. To date, GBV-C in most cases does not appear to cause any serious liver disease.